REVANCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 USD | +3.34% |
|
-10.05% | -61.32% |
| Apr. 26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
| Apr. 12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 4.130 | 5.190 | 10.60 |
| Spread/Res. | -17.68% | -34.49% | -67.92% |
| Spread/Supp. | +3.34% | +3.34% | +46.55% |
| Support | 3.290 | 3.290 | 2.320 |
Technical Rankings Surperformance
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- RVNC Stock
- Charts Revance Therapeutics, Inc.
